I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial

Cancer Journal

Volumn 8, Issue 1, 2002, Pages 67-73

  Wallner, Kent ^a,b   Merrick, Gregory ^c   True, Lawrence ^d   Cavanagh, William ^e   Simpson, Colleen ^a   Butler, Wayne ^c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WHEELING HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Prostatic carcinoma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE SEVERITY; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; STANDARD; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDENT T TEST; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT OBSTRUCTION; BRACHYTHERAPY; CARCINOMA; COMPARATIVE STUDY; HALF LIFE TIME; METHODOLOGY; MICTURITION DISORDER; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIATION EXPOSURE; RECTUM;

AGED; BRACHYTHERAPY; CARCINOMA; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECTUM; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 0036364463     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-87.
2. Cha CM, Potters L, Ashley R et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;45:391-395.
3. Peschel RE, Chen Z, Roberts K et al. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Invest 1999;7:278-288.
4. Nag S, Sweeney PJ, Wienthjes MG. Dose-response study of iodine-125 and palladium-103 brachytherapy in a rat prostate tumor (Nb-AI-1). Endocur/Hypertherm 1997;9:97-104.
5. Blasko JC, Grimm PD, Sylvester JE et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-278.
6. Dattoli M, Wallner K, True L et al. Prognostic role of serum prostatic acid phosphatase for 103-Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999;45:853-856.
7. Wallner K, Merrick G, True L et al. I-125 versus Pd-103 for low risk prostate cancer: preliminary urinary functional outcomes from a prospective randomized multicenter trial. J Brachyther Int 2000;16:151-155.
8. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endo/Hypertherm 1987;3:131-139.
9. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol 2000;6:78-84.
10. Han B, Wallner K, Aggarwal S et al. Treatment margins for prostate brachytherapy. Semin Urin Oncol 2000;18:137-141.
11. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urologic Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549.
12. Gelblum DY, Potters L, Ashley R et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
13. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-1382.